| Marketing of the life sciences: A new framework and research agenda for a nascent field S Stremersch, W Van Dyck Journal of Marketing 73 (4), 4-30, 2009 | 237 | 2009 |
| Barriers and opportunities for implementation of outcome-based spread payments for high-cost, one-shot curative therapies S Michelsen, S Nachi, W Van Dyck, S Simoens, I Huys Frontiers in pharmacology 11, 594446, 2020 | 35 | 2020 |
| Corporate venturing: Strategies and success factors B Leten, W Van Dyck Review of business and economic literature 57 (4), 242-257, 2012 | 34 | 2012 |
| Nearest neighbour propensity score matching and bootstrapping for estimating binary patient response in oncology: a Monte Carlo simulation T Geldof, D Popovic, N Van Damme, I Huys, W Van Dyck Scientific reports 10 (1), 964, 2020 | 32 | 2020 |
| Real-world evidence gathering in oncology: the need for a biomedical big data insight-providing federated network T Geldof, I Huys, W Van Dyck Frontiers in medicine 6, 43, 2019 | 18 | 2019 |
| Shedding light on reimbursement policies of companion diagnostics in European countries L Govaerts, S Simoens, W Van Dyck, I Huys Value in Health 23 (5), 606-615, 2020 | 16 | 2020 |
| Pharmaceutical discovery as a complex system of decisions: the case of front-loaded experimentation W Van Dyck, PM Allen Emergence-Mahwah-Lawrence Erlbaum- 8 (3), 40, 2006 | 14 | 2006 |
| Unlocking the value of personalised healthcare in Europe—breast cancer stratification W Van Dyck, D Gassull, G Vértes, P Jain, M Palaniappan, D Schulthess, ... Health policy and technology 1 (2), 63-68, 2012 | 12 | 2012 |
| Pharmaceutical net price transparency across European markets: insights from a multi-agent simulation model M Riccaboni, T Swoboda, W Van Dyck Health Policy 126 (6), 534-540, 2022 | 10 | 2022 |
| Acute coronary syndrome: What is the cost-effectiveness of prevention, point-of-care technology and telemonitoring? W Van Dyck, G Vértes, M Palaniappan, D Gassull, P Jain, D Schulthess, ... Health Policy and Technology 1 (3), 173-177, 2012 | 10 | 2012 |
| Building and leveraging your ecosystem to spark innovation-based growth W Van Dyck | 10 | 2012 |
| A systematic review of the value assessment frameworks used within health technology assessment of omics technologies and their actual adoption from HTA agencies I Hoxhaj, L Govaerts, S Simoens, W Van Dyck, I Huys, ... International journal of environmental research and public health 17 (21), 8001, 2020 | 8 | 2020 |
| Patient-level effectiveness prediction modeling for glioblastoma using classification trees T Geldof, N Van Damme, I Huys, W Van Dyck Frontiers in pharmacology 10, 1665, 2020 | 7 | 2020 |
| The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy’s multi-stakeholder pre-convention questionnaire L Van Haesendonck, J Ruof, T Desmet, W Van Dyck, S Simoens, I Huys, ... Journal of market access & health policy 11 (1), 2217543, 2023 | 6 | 2023 |
| Comparative and combined effectiveness of innovative therapies in cancer: a literature review T Geldof, S Rawal, WV Dyck, I Huys Journal of comparative effectiveness research 8 (4), 205-216, 2019 | 6 | 2019 |
| The future of access to innovative medicines in cancer therapy: Towards conditional dialogue fostering affordable therapeutic innovation W Van Dyck, J De Grève, R Schots, A Awada, T Geldof | 6 | 2016 |
| Predictive performance of front-loaded experimentation strategies in pharmaceutical discovery: A Bayesian perspective W Van Dyck Cranfield University, 2004 | 4 | 2004 |
| The Oncology horizon scanning project W Van Dyck, T Geldof Vlerick HMC Report 1, 2015 | 3 | 2015 |
| The balancing act of innovation W Van Dyck, P Silberzahn Lannoo Meulenhoff-Belgium, 2011 | 3 | 2011 |
| Does constructive feedback improve idea quality in idea contests? Exploring the role of hierarchy and feedback overlap M Boënne, B Leten, W Van Dyck R&D Management 53 (3), 345-363, 2023 | 2 | 2023 |
